I think people are worried that Immutep is going to be sold off too cheaply. Management aren't silly and they understand the market. There are preclinical biotechs with MC higher than Immutep's MC. I think some of the reasons as to why our MC is so low, is due to perception. We are an Australian biotech with dual listing. People get confused with the different share prices, the ADR ratio, exchange rate etc. It all gets too hard and they look elsewhere. If we were an American biotech our MC would be twice or three times what it is now.
Media, page-79
-
- There are more pages in this discussion • 665 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $551.9M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 39.0¢ | 37.0¢ | $1.296M | 3.401M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 54900 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 22008 | 1 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |